DiversifyRx
NOVEMBER 24, 2023
This tracking involves the use of unique product identifiers, such as serial numbers and barcodes, on drug packaging to track their movement. This record-keeping includes detailed documentation of the product’s history and movement through the supply chain. It also enables precise tracking and tracing of each drug package.
The FDA Law Blog
JULY 10, 2023
FDA communicates via a Substantive Interaction to inform the submitter either that FDA will proceed with Interactive Review or that the 510(k) will be placed on hold until FDA receives a complete response to an Additional Information request. By Day 15 FDA conducts Acceptance Review. By Day 60 FDA conducts Substantive Review.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 27, 2022
The overarching principle set out in Codes of Practice, and in particular the Principles for the use of digital channels in the EFPIA Code , is that the legislation and Codes of Practice apply equally to communications by companies on social media and digital channels.
European Pharmaceutical Review
JANUARY 25, 2024
These standardised documents provide meticulously curated and scientifically approved information. 7 Access to digital communications also remains a challenge in some Member States especially for those groups at risk of poverty and social exclusion (7.6 percent as EU average with some Member States as high as 25 percent).
The Checkup by Singlecare
MARCH 16, 2023
This includes counting, measuring, and packaging medications, as well as labeling and organizing them for distribution. They work closely with pharmacists to ensure that medications are prepared and dispensed accurately and safely,” he says.
pharmaphorum
FEBRUARY 2, 2022
Through a series of workshops and surveys, which collected the views of research professionals, patients and carers, the group has developed a new guidance document. But how do we package that up?” A practical consensus. Everything has moved so quickly.
The FDA Law Blog
NOVEMBER 2, 2023
CBER may still request additional information when deemed appropriate, but the stated hope is that increased use of VCS can facilitate product development by reducing the need to develop unique methods for individual products and that they will typically reduce the amount of necessary documentation “and may reduce FDA review time.”
Expert insights. Personalized for you.
52 
Let's personalize your content